Company Profile For Acucela

Published: Oct 06, 2017

--(BUSINESS WIRE)--Acucela Inc., is a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596) committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore vision for millions of people worldwide. Acucela’s development pipeline include drug candidates and therapeutics for the treatment of retinitis pigmentosa, proliferative diabetic retinopathy, diabetic macular edema, AMD, Stargardt disease, cataracts and presbyopia. The company is also developing a monitoring device for neovascular retinal diseases, to be used directly by patients.

Company: Acucela Inc.
Headquarters Address: 818 Stewart St., Suite 1110
Seattle, WA 98101
Main Telephone:



Type of Organization: Private


Biotechnology, Medical Devices, Pharmaceutical

Key Executives: CEO: Ryo Kubota, MD, PhD
Public Relations
Contact: Michael Hasegawa



Investor Relations
Contact: John Gebhart
Phone: +1-206-805-3972

Back to news